Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma

J. U. Gutterman, G. R. Blumenschein, R. Alexanian, H. Y. Yap, A. U. Buzdar, F. Cabanillas, G. N. Hortobagyi, Evan M Hersh, S. L. Rasmussen, M. Harmon, M. Kramer, S. Pestka

Research output: Contribution to journalArticle

368 Citations (Scopus)

Abstract

38 Patients with advanced breast cancer, multiple myeloma, and malignant lymphoma were treated with partially purified (about 0.1%) leukocyte interferon. Patients were treated with a remission-induction schedule of 3 million to 9 million antiviral units daily intramuscularly for 4 to 26 weeks. Responding patients were maintained on a schedule of 3 million U three times weekly. Tumor regression was observed in seven of 17 patients with breast cancer. Six of 10 patients with multiple myeloma responded with a decrease of at least 50% in serum myeloma protein levels or Bence Jones protein excretion. Six of the 11 lymphoma patients achieved tumor regression. Complete remissions occurred in two patients. Of the 19 responding patients, five remain on study for 52 to 63 weeks. Toxicity included low-grade fever, fatigue, anorexia, and partial alopecia. Myelosuppression (lowest median leukocyte count, 2500/mm 3; granulocytes, 1300/mm 3) occurred in most patients. On the basis of this pilot study, we conclude that leukocyte interferon can induce tumor regression in patients with advanced cancer.

Original languageEnglish (US)
Pages (from-to)399-406
Number of pages8
JournalAnnals of Internal Medicine
Volume93
Issue number3
StatePublished - 1980
Externally publishedYes

Fingerprint

Multiple Myeloma
Interferon-alpha
Lymphoma
Breast Neoplasms
Neoplasms
Appointments and Schedules
Bence Jones Protein
Myeloma Proteins
Remission Induction
Alopecia
Anorexia
Leukocyte Count
Granulocytes
Antiviral Agents
Fatigue
Blood Proteins
Fever

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gutterman, J. U., Blumenschein, G. R., Alexanian, R., Yap, H. Y., Buzdar, A. U., Cabanillas, F., ... Pestka, S. (1980). Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Annals of Internal Medicine, 93(3), 399-406.

Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. / Gutterman, J. U.; Blumenschein, G. R.; Alexanian, R.; Yap, H. Y.; Buzdar, A. U.; Cabanillas, F.; Hortobagyi, G. N.; Hersh, Evan M; Rasmussen, S. L.; Harmon, M.; Kramer, M.; Pestka, S.

In: Annals of Internal Medicine, Vol. 93, No. 3, 1980, p. 399-406.

Research output: Contribution to journalArticle

Gutterman, JU, Blumenschein, GR, Alexanian, R, Yap, HY, Buzdar, AU, Cabanillas, F, Hortobagyi, GN, Hersh, EM, Rasmussen, SL, Harmon, M, Kramer, M & Pestka, S 1980, 'Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma', Annals of Internal Medicine, vol. 93, no. 3, pp. 399-406.
Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Annals of Internal Medicine. 1980;93(3):399-406.
Gutterman, J. U. ; Blumenschein, G. R. ; Alexanian, R. ; Yap, H. Y. ; Buzdar, A. U. ; Cabanillas, F. ; Hortobagyi, G. N. ; Hersh, Evan M ; Rasmussen, S. L. ; Harmon, M. ; Kramer, M. ; Pestka, S. / Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. In: Annals of Internal Medicine. 1980 ; Vol. 93, No. 3. pp. 399-406.
@article{bae8b72c21ae4f8a91aee917975a1b9a,
title = "Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma",
abstract = "38 Patients with advanced breast cancer, multiple myeloma, and malignant lymphoma were treated with partially purified (about 0.1{\%}) leukocyte interferon. Patients were treated with a remission-induction schedule of 3 million to 9 million antiviral units daily intramuscularly for 4 to 26 weeks. Responding patients were maintained on a schedule of 3 million U three times weekly. Tumor regression was observed in seven of 17 patients with breast cancer. Six of 10 patients with multiple myeloma responded with a decrease of at least 50{\%} in serum myeloma protein levels or Bence Jones protein excretion. Six of the 11 lymphoma patients achieved tumor regression. Complete remissions occurred in two patients. Of the 19 responding patients, five remain on study for 52 to 63 weeks. Toxicity included low-grade fever, fatigue, anorexia, and partial alopecia. Myelosuppression (lowest median leukocyte count, 2500/mm 3; granulocytes, 1300/mm 3) occurred in most patients. On the basis of this pilot study, we conclude that leukocyte interferon can induce tumor regression in patients with advanced cancer.",
author = "Gutterman, {J. U.} and Blumenschein, {G. R.} and R. Alexanian and Yap, {H. Y.} and Buzdar, {A. U.} and F. Cabanillas and Hortobagyi, {G. N.} and Hersh, {Evan M} and Rasmussen, {S. L.} and M. Harmon and M. Kramer and S. Pestka",
year = "1980",
language = "English (US)",
volume = "93",
pages = "399--406",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma

AU - Gutterman, J. U.

AU - Blumenschein, G. R.

AU - Alexanian, R.

AU - Yap, H. Y.

AU - Buzdar, A. U.

AU - Cabanillas, F.

AU - Hortobagyi, G. N.

AU - Hersh, Evan M

AU - Rasmussen, S. L.

AU - Harmon, M.

AU - Kramer, M.

AU - Pestka, S.

PY - 1980

Y1 - 1980

N2 - 38 Patients with advanced breast cancer, multiple myeloma, and malignant lymphoma were treated with partially purified (about 0.1%) leukocyte interferon. Patients were treated with a remission-induction schedule of 3 million to 9 million antiviral units daily intramuscularly for 4 to 26 weeks. Responding patients were maintained on a schedule of 3 million U three times weekly. Tumor regression was observed in seven of 17 patients with breast cancer. Six of 10 patients with multiple myeloma responded with a decrease of at least 50% in serum myeloma protein levels or Bence Jones protein excretion. Six of the 11 lymphoma patients achieved tumor regression. Complete remissions occurred in two patients. Of the 19 responding patients, five remain on study for 52 to 63 weeks. Toxicity included low-grade fever, fatigue, anorexia, and partial alopecia. Myelosuppression (lowest median leukocyte count, 2500/mm 3; granulocytes, 1300/mm 3) occurred in most patients. On the basis of this pilot study, we conclude that leukocyte interferon can induce tumor regression in patients with advanced cancer.

AB - 38 Patients with advanced breast cancer, multiple myeloma, and malignant lymphoma were treated with partially purified (about 0.1%) leukocyte interferon. Patients were treated with a remission-induction schedule of 3 million to 9 million antiviral units daily intramuscularly for 4 to 26 weeks. Responding patients were maintained on a schedule of 3 million U three times weekly. Tumor regression was observed in seven of 17 patients with breast cancer. Six of 10 patients with multiple myeloma responded with a decrease of at least 50% in serum myeloma protein levels or Bence Jones protein excretion. Six of the 11 lymphoma patients achieved tumor regression. Complete remissions occurred in two patients. Of the 19 responding patients, five remain on study for 52 to 63 weeks. Toxicity included low-grade fever, fatigue, anorexia, and partial alopecia. Myelosuppression (lowest median leukocyte count, 2500/mm 3; granulocytes, 1300/mm 3) occurred in most patients. On the basis of this pilot study, we conclude that leukocyte interferon can induce tumor regression in patients with advanced cancer.

UR - http://www.scopus.com/inward/record.url?scp=0018824574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018824574&partnerID=8YFLogxK

M3 - Article

VL - 93

SP - 399

EP - 406

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -